Q2 2026 OraSure Technologies Inc Earnings Call Transcript
Key Points
- OraSure Technologies Inc (OSUR) exceeded its Q2 2026 revenue guidance, with total revenue of $30.6 million, growing 9.7% sequentially.
- Gross margins expanded sequentially, with GAAP gross margin up 120 basis points to 43.5% and non-GAAP gross margin up to 44.2%, driven by lower scrap and operational efficiencies.
- The company achieved significant regulatory milestones, including FDA clearance for the Colli-Pee Dx urine collection kit and FDA Emergency Use Authorization for the OraQuick Ebola 2.0 Rapid Test.
- Sickle SCAN revenue is growing twice as fast in 2026 compared to 2025, reflecting successful integration into international commercial channels.
- The company maintains a strong balance sheet with zero debt and $161 million in cash, and has returned $22 million to shareholders through share repurchases, representing nearly 10% of outstanding shares.
- Sample Management Solutions revenue grew 9% sequentially, with growth across segments and early signs of recovery in academic and research channels.
- OraSure Technologies Inc (OSUR) withdrew its FDA submission for the InteliQuick CT/NG test, delaying expected clearance and US launch beyond 2026.
- The company recorded a reduction in its contingent consideration liability due to the updated submission plan for the CT/NG test, indicating a delay in milestone payments.
- G&A expenses increased year-over-year due to non-recurring items, including higher legal and professional service costs related to proxy and stockholder activism.
- The company paused additional share repurchase activity during the quarter to prioritize balance sheet flexibility for launch-related investments.
- Despite progress, the company still reported a non-GAAP operating loss of $14.7 million in Q2, indicating ongoing profitability challenges.
- The delay in InteliQuick CT/NG clearance could impact future revenue growth expectations, although the company maintains its 2026 growth outlook.
Good day, and thank you for standing by. Welcome to OraSure Technologies Inc. 2026 second-quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Michelle Anthony, Chief Accounting Officer. Please go ahead.
Thank you. Good afternoon and welcome to OraSure Technologies' second-quarter 2026 earnings call. Participating in the call today for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer; and Ken McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded, and the recording can be found on our Investor Relations website.
Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, and other financial performance, product development, performance, shipments
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
